Neuroendocrine tumours (NET) are a rare and heterogeneous group of neoplasms.
INTROdUcTION
Neuroendocrine tumours (NET) are a heterogeneous group of rare neoplasms. Most of them are non-functioning, which is why they are diagnosed at an advanced stage only, making radical surgical treatment impossible. The course of the disease varies too, ranging from relatively mild local lesions to aggressive and quickly metastasising ones. Hence, patient prognosis may be very different, with 5-year survival ranging from 15% to 95%, depending on the case in question [1, 2] .
Biological properties of neuroendocrine tumours, related to the expression of many growth factors and their receptors, including VEGF (vascular endothelial growth factor), PDGF (platelet derived growth factor) and their receptors, bFGF (basic fibroblast growth factor), IGF1 and its receptor (IGF1R, insulin-like growth factor receptor), EGF (epidermal growth factor) and its receptor EGFR (epidermal growth factor receptor), c-MET (hepatocyte growth factor receptor) and somatostatin receptors, and the fact that the tumours are highly vascularized extend the possibilities of treatment involving biologics or molecular targeted agents [4] . mTOR signalling pathways mTOR (mammalian target of rapamycin) is presently considered to be a new and important target in the treatment of neuroendocrine tumours. mTOR is an intracellular serine/threonine protein kinase, acting as the main regulator of cell proliferation, angiogenesis and metabolism. It is a key intracellular meeting point of many signalling pathways which are abnormally activated in neoplasms [5] .
The PI3K/AKT/mTOR sIgNAllINg PAThwAy
The PI3K (phosphatidylinositol 3-kinase)/AKT/mTOR signalling cascade is one of the chief signalling pathways related to the activity of receptor tyrosine kinases (RTKs) in cancer cells [6] .
RTK activation leads to autophosphorylation of the cytoplasmic domain, which subsequently interacts with the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K). The subunit may also be indirectly activated by contact with insulin receptor substrates (IRS-1/2) [7] . As a result of p85 activation, the p110 catalytic subunit of PI3K is stimulated. The p110 subunit mediates conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol 3,4,5-trisphosphate (PIP3). Additionally, PI3K may undergo activation via direct contact of RAS with the p110 subunit [6] . PI3K activity is inhibited by PTEN (phosphatase and tensin homolog), responsible for PIP3 dephosphorylation. PIP3 activates the AKT serine/threonine kinase on the internal surface of cell membrane, followed by AKT phosphorylation of a series of proteins involved in proliferation and apoptosis control within the cytoplasm and the nucleus [8] .
One of the key elements activated by AKT is the mTOR serine/ threonine kinase. The TOR protein family performs different functions and participates in the regulation of many cellular processes and protein translations. It is involved in the organization of the actin cytoskeleton, relocation of intracytoplasmic structures, degradation of proteins, signalling cascade of the C protein kinase, and in the ribosomal biogenesis [9, 10] . The mTOR protein regulates important signalling pathways that activate cellular proliferation, modulating and transmitting signals from the membrane receptors [11] . The mTOR protein is to be found in two structurally distinct complexes: mTORC1 and mTORC2. Both of the complexes additionally contain the GbL protein (G protein β-subunit-like protein), and the raptor (regulatory-associated protein of mTOR in mTORC1) or rictor (rapamycin-insensitive companion of mTOR in mTORC2) proteins [11] [12] [13] [14] [15] . The mTORC1 complex phosphorylates effector proteins, the S6 kinase 1 (S6K1, p70S6K) and the 4EBP1 protein binding the early eukaryotic initiation factor 4E (eIF4E), which control the translation of particular genes [12] . On the other hand, mTORC2 controls the actin cytoskeleton, and regulates the activity of AKT/PKB [16, 17] . Phosphorylated AKT may activate mTORC1 via 2 pathways involving the TSC1/TSC2 complex or the PRAS40 protein [18] . In a cell which contains an adequate amount of nutrients, AKT inactivates the TSC1/ TSC2 tumour suppressor complex [19] . The inactivated TSC1/ TSC2 complex ceases to inhibit the activity of the GTP-binding protein, which can directly activate the mTORC1 complex.
Phosphorylation of the PRAS40 protein by AKT switches off its inhibitory impact on mTORC1 [18] . It appears that the less known mTORC2 complex also plays an important part in neoplastic cells. mTORC2 acts as the phosphoinositide-dependent kinase-2 (PDK2), causing AKT phosphorylation. As a result, the FOXO proteins, performing the function of a transcription factor and apoptosis activator, undergo phosphorylation and inactivation [20] . Moreover, TORC2 is also responsible for the transcription of two hypoxia-inducible factors, HIF-1a and HIF-2a [21] , which determine the malignant phenotype of neoplastic cells, and are responsible for resistance to chemotherapy. frequently observed in neuroendocrine tumours [22] . Based on gene expression profiling, the role of PI3K/AKT/mTOR in the development of sporadic pancreatic NETs has been confirmed [23] [24] [25] . Analysis of the molecular mechanisms behind neuroendocrine tumours has demonstrated that predisposition to NET is related to the damage of the PTEN suppressor gene, and consequently to the lack of activity of the PTEN phosphatase [24, 25] . Additionally, genome sequence analysis of sporadic pancreatic NETs has demonstrated somatic mutations in around 15% of the mTOR pathway-related genes: PTEN, TSC2 and PIK-3CA [22, 23] . The PTEN gene mutations are rare and account for only around 7-9% of the cases [25] [26] [27] . Additionally, in one third of the sporadic pancreatic NETs, deletion of 10q (PTEN) as well as deletion of 16p (TSC2) has been reported [28, 29] . Reduced expression of TSC2 as well as PTEN, a gene regulating the mTOR activity via the PI3K/AKT pathway, has been observed in 75% of the pancreatic NET patients [23] . Low PTEN expression appears to be associated with a shorter time to disease progression, and shorter median survival [23] . Recent findings point to the different expression of mTOR and mTOR-related proteins depending on the tumour primary location. The expression is higher in foregut tumours as compared to the midgut ones [30] .
It has also been shown that in the case of midgut NET tumours, the TSC1 and TSC2 expression is normal, unlike in the pancreatic NETs, where low expression of PTEN, TSC1 and TSC2 is reported [25] . The results indicate different mechanisms behind the mTOR pathway activation in neuroendocrine tumours of different primary foci [31] .
Most NETs are sporadic, but there is a small group of neuroendocrine tumours which form part of familial genetic syndromes.
A small group of patients (< 5%) suffering from neurofibromatosis type 1 (NF1) develop catecholamine-producing tumours or neuroendocrine tumours involving the duodenal papilla. The NF1 gene encodes the neurofibromin protein, which inhibits the PI3K/AKT/mTOR pathway via RAS suppression. In patients with tuberous sclerosis (TS), tumours are related to the inactivity of the TSC1 and TSC2 suppressor genes, and they are also regulated by neurofibromin thanks to the mTOR pathway activation [32] . Tumour mass reduction by over 50% was reported in 56% and 49% of the subjects, respectively. Additionally, there was a correlation between the reduced concentration of chromogranin A and median PFS. The treatment was well-tolerated by the patients involved. There were very few grade 3 and 4 adverse events, including oral mucositis, fatigue, and diarrhoea [35] . and hyperglycaemia (5%) [37] . vs. 37%, respectively [41] .
The most recent study, RADIANT-4, included 302 patients with neuroendocrine tumours of GI or lung origin (30% of the study subjects had lung lesions, and 24% of them had colorectal lesions) with confirmed progression. All patients were offered best supportive care, and they were randomized 
